FL-NCIPHER-SECURITY
nCipher Security, an Entrust Datacard company and provider of trust, integrity and control for business critical information and applications, announces two new additions to its nShield® hardware security module (HSM) portfolio – nShield Web Services Option Pack and nShield Container Option Pack – that make it simpler to deploy applications in the cloud and bring greater security and control to public and private clouds.
nShield Web Services Option Pack simplifies deployment for cloud-first data centres. nShield Web Services Option Pack provides a REST API between applications requiring cryptographic key and data protection services and nShield HSMs, enabling seamless application deployment underpinned by high-assurance nShield HSMs, which can dynamically scale to meet the needs of cloud-ready data centers. Customers can also use their own load balancing appliances to handle the HSM workload, simplifying the HSM deployment and configuration, and ensuring the best utilization of their HSM pools.
nShield Container Option Pack enables nShield HSMs to operate seamlessly within a containerized environment. Containerization has become the model of choice in forward-thinking cloud and enterprise deployments, offering scaling, flexibility and orchestration. The nShield Container Option Pack allows developers to leverage the advantages of container platforms while accessing a high-assurance nShield HSM. The nShield HSM processes sensitive data and key material, reducing the time required to develop and deploy secure containerized applications. nShield HSMs offer a uniquely seamless integration with application containers, making it easy to build HSM support into containerized solutions. The nShield Container Option Pack provides a template deployment model that allows customers to focus on the containerized application without having to worry about HSM integration.
“One of the biggest drivers of digital transformation is the widespread enterprise adoption of cloud-- IDC predicts that 70% of new enterprises applications will be developed cloud native by 2021,” says Peter Galvin, chief strategy officer for nCipher Security. “As organizations increasingly adopt cloud -first strategies and operate in multi-cloud environments, security concerns remain – from visibility into the data protection architecture to managing complex security policies and encryption keys that secure applications and data.”
“The new nShield Web Services Option Pack and nShield Container Option Pack help cut development times and budgets, allowing customer to harness cloud platforms without losing control of their keys or their data,” said Galvin.
nCipher’s nShield HSM portfolio also includes the following solutions for customers pursuing a cloud first strategy:
nShield as a Service
A subscription-based service which provides development and deployment teams with streamlined access to dedicated cloud-based nShield Connect HSMs, allowing organizations to migrate to cloud-centric strategies while also maintaining strict security controls required for business-critical applications. This supports changing business preferences for operational instead of capital expenses, aligns with modern development workflows and decreases the time spent by security personnel on maintenance and monitoring tasks.
Bring Your Own Key
Used in conjunction with nShield HSMs you can Bring Your Own Keys (BYOK) to your cloud applications, whether you are using Amazon Web Services (AWS), Google Cloud Platform (GCP) or Microsoft Azure.
nShield high-assurance HSMs enable customers to continue to benefit from the flexibility and economy of cloud services, while strengthening the security of their key management practices and gaining greater control over their keys. To find out more about our solutions click here .
nCipher Security and Entrust Datacard will be exhibiting at RSA Conference 2020 on booth #S-2139 . Drop by to learn how our cryptographic solutions guard against today’s threats and attacks, enable compliance and protect your business applications.
About nCipher Security
nCipher Security, an Entrust Datacard company, is a leader in the general-purpose hardware security module (HSM) market, empowering world-leading organizations by delivering trust, integrity and control to their business-critical information and applications. Today’s fast-moving digital environment enhances customer satisfaction, gives competitive advantage and improves operational efficiency – it also multiplies the security risks. Our cryptographic solutions secure emerging technologies such as cloud, IoT, blockchain, and digital payments and help meet new compliance mandates. We do this using our same proven technology that global organizations depend on today to protect against threats to their sensitive data, network communications and enterprise infrastructure. We deliver trust for your business-critical applications, ensure the integrity of your data and put you in complete control – today, tomorrow, always. www.ncipher.com
Follow us on LinkedIn , Twitter , Facebook and Instagram – search nCipherSecurity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200129005210/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom